TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32740409
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg once daily, n=9)
Study: 32740409
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg once daily, n=7)
Study: 32740409
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg once daily)
Study: 36265052
Drug: 0.60 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.60 g/kg alcohol
Study: 32238262
Drug: Antibiotic-impregnated shunt
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic-impregnated shunt
Study: 32552530
Drug: Laughter yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laughter yoga (LY) twice weekly for 8 weeks
Study: 32552530
Drug: Routine daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine daily activities (Control)
Study: 33165588
Drug: Availability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Availability of medicines and supplies for communicable diseases
Study: 33165588
Drug: Availability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Availability of medicines and supplies for maternal health services
Study: 34344427
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (450 mg, two capsules twice a day for 14 days)
Study: 34344427
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules twice a day for 14 days)
Study: 39541403
Drug: Cisplatin treatment
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin treatment
Study: 34213544
Drug: High-dose prenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prenatal plus postpartum vitamin D (28,000 IU per week)
Study: 34246303
Drug: LOW (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW (1.5 g/kg carbohydrate, 3.0 g/kg fat)
Study: 34246303
Drug: AD (6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD (6.0 g/kg carbohydrate, 1.0 g/kg fat)
Study: 34945234
Drug: Remote hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote hospital care including oxygen therapy, medication, and remote monitoring.
Study: 35662283
Drug: Nivolumab (nivo)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (nivo) with chemotherapy (gemcitabine/nab-paclitaxel)
Study: 35662283
Drug: Sotigalimab (sotiga)
Normalized name: Sotigalimab
DrugBank: Sotigalimab (DB16413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotigalimab (sotiga) with chemotherapy (gemcitabine/nab-paclitaxel)
Study: 35662283
Drug: Sotigalimab (sotiga)
Normalized name: Sotigalimab
DrugBank: Sotigalimab (DB16413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotigalimab (sotiga) with nivolumab (nivo) and chemotherapy (gemcitabine/nab-paclitaxel)
Study: 36691184
Drug: Post-chemotherapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-chemotherapy
Study: 36342113
Drug: Pemafibrate (0.2-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate (0.2-mg tablets twice daily)
Study: 36978099
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy
Study: 34501540
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention program (interactive oral activities, tongue strength training, oral cleaning procedure)
Study: 33615398
Drug: CBT combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT combined with medication (CBT + M)
Study: 33615398
Drug: Medication only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only (M)
Study: 34347808
Drug: Oral phloroglucinol
Normalized name: phloroglucinol
DrugBank: Phloroglucinol (DB12944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phloroglucinol (Flospan®)
Study: 32600320
Drug: Lactose challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose challenge (50 g lactose)
Study: 32600320
Drug: Conventional milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional milk (750 mL, 37.5 g lactose)
Study: 32600320
Drug: A1 β-casein-free
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: A1 β-casein-free milk (a2 Milk™) (750 mL, 37.5 g lactose)
Study: 33422174
Drug: Methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate monotherapy 20 mg once a week
Study: 33422174
Drug: Hydroxychloroquine 400
Normalized name: hydroxychloroquine 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg daily with topical minoxidil
Study: 33866774
Drug: DPP-4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitor (gemigliptin)
Study: 33866774
Drug: DPP-4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitor (sitagliptin)
Study: 34410358
Drug: Cipargamin (KAE609)
Normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipargamin (KAE609) single doses of 50 to 150 mg
Study: 33522951
Drug: Homeopathy: 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathy: 1 globule of Natrum muriaticum LM2 diluted in 20 mL of alcohol 30%, taken orally every 4 hours while symptomatic, then every 6 hours until the fourteenth day.
Study: 33522951
Drug: Placebo: 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 20 mL of alcohol 30% dispensed in a 30 ml bottle, taken orally every 4 hours while symptomatic, then every 6 hours until the fourteenth day.
Study: 32515740
Drug: Coach-guided web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coach-guided web-based therapy (The Journal) for 12 weeks
Study: 36805437
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist trigger
Study: 34130573
Drug: Proactive management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive management with Cal/BD foam (twice-weekly application)
Study: 34130573
Drug: Reactive management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive management with Cal/BD foam (once-daily for four weeks after relapse)
Study: 33548084
Drug: Quadruple single-pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple single-pill combination (reserpine 0.1 mg, dihydralazine 12.5 mg, hydrochlorothiazide 12.5 mg, triamterene 12.5 mg)
Study: 33548084
Drug: Quadruple single-pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple single-pill combination
Study: 34677005
Drug: Hypochlorite-based formula
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypochlorite-based formula brushing solution
Study: 32969733
Drug: Hydromorphone 1
Normalized name: HYDROMORPHONE 1MG/ML NS INJ 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 1 mg/kg
Study: 32969733
Drug: Hydromorphone 2
Normalized name: HYDROmorphone 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 2 mg/kg
Study: 32969733
Drug: Hydromorphone 1
Normalized name: HYDROMORPHONE 1MG/ML NS INJ 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 1 mg/kg and 2 mg/kg
Study: 33516795
Drug: Incisional negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional negative pressure wound therapy (NPWT)
Study: 34741103
Drug: Rotarix (live‐attenuated,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotarix (live‐attenuated, oral rotavirus vaccine)
Study: 32609331
Drug: Icosapent Ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent Ethyl (IPE) 4 g/day
Study: 35064942
Drug: Ethanol (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (approximately 0.7 ml/kg)
Study: 34620496
Drug: Ceralasertib 160
Normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceralasertib 160 mg orally daily (days 1-7) and olaparib 300 mg orally twice daily (days 1-28) of a 28-day cycle until toxicity or progression
Study: 35462033
Drug: Guideline-Directed Medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-Directed Medical Therapy (GDMT)
Study: 35462033
Drug: Angiotensin-converting enzymes/angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzymes/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors
Study: 35048423
Drug: AZ-009 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZ-009 (2 mg)
Study: 35048423
Drug: AZ-009 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZ-009 (3 mg)
Study: 35048423
Drug: AZ-009 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZ-009 (4 mg)
Study: 33268527
Drug: Active conventional
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active conventional treatment (either prednisolone tapered to 5 mg/day, or sulfasalazine combined with hydroxychloroquine and intra‐articular corticosteroids)
Study: 35810757
Drug: Bridging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy (intravenous thrombolytic before endovascular thrombectomy)
Study: 34727741
Drug: Bridging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy
Study: 34155159
Drug: Intravenous Dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Dexmedetomidine (DEX) administered at an initial dose of 1 µg/kg over 10 minutes, followed by a continuous infusion at 0.4 μg/kg/h until 30 minutes before the end of surgery.
Study: 34155159
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral superficial cervical plexus block (SCPB) with 10 mL of 0.375% ropivacaine injected on each side.
Study: 34155159
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline administered at the same rate and dose as in group D.
Study: 35139044
Drug: Intrathecal chloroprocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal chloroprocaine 49.5 mg with fentanyl 10 ug
Study: 36188435
Drug: RQ3013 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: RQ3013 (30 μg mRNA per 0.15 mL)
Study: 36188435
Drug: ChAdTS-S (5×10^10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdTS-S (5×10^10 viral particles per 0.5 mL)
Study: 36188435
Drug: ZR202-CoV (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZR202-CoV (25 μg per 0.5 mL)
Study: 36188435
Drug: CoronaVac (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac (3 μg inactivated CN02 strain of SARS-CoV-2 per 0.5 mL)
Study: 36188435
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 mL of 0.9% sodium chloride solution)
Study: 35633654
Drug: Inulin+Traditional Chinese
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin+Traditional Chinese Medicine (TCM)
Study: 35633654
Drug: Inulin+Metformin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin+Metformin
Study: 32789480
Drug: PCb (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCb (paclitaxel 80 mg/m2 and carboplatin [AUC = 2] on days 1, 8, and 15 every 28 days for 6 cycles)
Study: 32789480
Drug: CEF-T (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF-T (cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2, and fluorouracil 500 mg/m2 every 3 weeks for 3 cycles followed by docetaxel 100 mg/m2 every 3 weeks for 3 cycles)
Study: 35869929
Drug: HDIT101 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDIT101 (doses up to 12,150 mg)
Study: 35967104
Drug: Atacicept 25
Normalized name: Atacicept
DrugBank: Atacicept (DB06399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept 25 mg
Study: 33503610
Drug: One Strength
Normalized name: Voltaren Joint Health And Bone Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Strength Group (3 injections with 1 strength B, 10,000 TU/mL)
Study: 33503610
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group (7 injections with 2 strengths A (1,000 TU/mL) and B (10,000 TU/mL))
Study: 33070326
Drug: Water as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water as a neutralising agent
Study: 33070326
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate plus solution (Control)
Study: 36335517
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg/d)
Study: 34515079
Drug: Osteopathic medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic medicine (OM) sessions (up to six sessions) in addition to routine care
Study: 35638455
Drug: 3% NaCl
Normalized name: LVP solution Dextrose 5% with 0.3% NaCl intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% NaCl solution
Study: 36077145
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (200 µg or 8000 IU)
Study: 33407848
Drug: Tailored Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored Intervention (TI) including one face-to-face counseling session incorporating cognitive behavioral therapy and 30 days of 2-way text messaging
Study: 34158786
Drug: Non-adherence to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adherence to antihypertensive medications (AHTNM)
Study: 34158786
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of antihypertensive medications (AHTNM)
Study: 32265309
Drug: Inhaled Aztreonam
Normalized name: aztreonam Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Aztreonam
Study: 34315508
Drug: Proprioceptive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprioceptive training with Flexibar® (9 min daily for 12 weeks)
Study: 34315508
Drug: Proprioceptive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprioceptive training with Flexibar® (9 min daily for 12 weeks) and at least 40 min running or walking/week with XCO®
Study: 35213109
Drug: Low‐Level Light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐Level Light Amplification by Stimulated Emission of Radiation therapy (LLLT) using Diode LASER
Study: 35213109
Drug: Topical Anginovag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Anginovag spray medication
Study: 35213109
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with motivation and follow‐up
Study: 34792562
Drug: TTV cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTV cut-off level of 1.2 × 10^6 c/ml at month 3
Study: 32212089
Drug: Sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib plus Metformin (arm A)
Study: 32402609
Drug: Remotely supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remotely supervised cranial electrical stimulation (CES) for 10 daily sessions (60 min each) over two weeks
Study: 35719338
Drug: High-dose VA
Normalized name: Fluzone 2023-2024 high-dose vaccine Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose VA therapy (amoxicillin 1 g t.i.d. and VPZ 20 mg b.i.d.)
Study: 35719338
Drug: Low-dose VA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose VA therapy (amoxicillin 1 g b.i.d. and VPZ 20 mg b.i.d.)
Study: 33320103
Drug: Dance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance and yoga intervention (twice weekly for 8 months)
Study: 32179906
Drug: Multimatrix mesalazine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimatrix mesalazine (combined dose groups, 2.4 or 4.8 g/day)
Study: 34886746
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (60 mL, placebo)
Study: 36412382
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume (HTV) ventilation, 12-15 mL/kg (group H)
Study: 36412382
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (LTV) ventilation, 6-8 mL/kg (group L)
Study: 32063059
Drug: Aprocitentan 10
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan 10 mg
Study: 32063059
Drug: Aprocitentan 25
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan 25 mg
Study: 32063059
Drug: Aprocitentan 50
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan 50 mg
Study: 32063059
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg (positive control)
Study: 34491022
Drug: aboBoNT‐A 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: aboBoNT‐A 50 U (5 injections of 0.1 mL each)
Study: 32267205
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose regimen (TDF 200 mg, efavirenz 400 mg, lamivudine 300 mg)
Study: 32267205
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose regimen
Study: 32267205
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose regimen and Standard dose regimen
Study: 32348700
Drug: Combined screening
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined screening and treatment program targeting psychological distress
Study: 35197490
Drug: Transcranial Magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Magnetic Stimulation (TMS) sessions daily over five consecutive days
Study: 36107715
Drug: Dopamine D2/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2/3 receptor availability (BPND) in people who smoke
Study: 33686407
Drug: Standard 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 150 IU dose proposed by the OPTIMIST trial
Study: 33686407
Drug: Starting dose
Normalized name: Austedo 6 MG Starting Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose >300 IU
Study: 35477876
Drug: App conditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: App conditional feedback group (250 patients) using the medication reminder app for medication and BP check alarms.
Study: 35477876
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (250 patients).
Study: 33337995
Drug: Anti-citrullinated peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-citrullinated peptide antibodies (ACPA) positive subjects
Study: 33399175
Drug: Maitland therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maitland therapy (central or unilateral postero‐anterior pressure) for 2 sessions/week for 3 weeks
Study: 34059737
Drug: Program B
Normalized name: ZINC OXIDE 3 g in 100 g / OCTOCRYLENE 6 g in 100 g / ENSULIZOLE 4 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g TOPICAL CREAM [NECK DECOLLETE HAND ARM DAY REPARATIVE HYDRATION RESCUE AND REPROGRAM BROAD SPECTRUM SPF 35 SUNSCREEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program B (fixed-order, internet cognitive behavioral therapy, iCBT)
Study: 32918160
Drug: Commercial formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial formulation
Study: 35361325
Drug: Cream-based formulation
Normalized name: phenylephrine hydrochloride / shark liver oil Rectal Cream [Formulation R]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream-based formulation
Study: 35361325
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment area
Study: 35118971
Drug: Tablet-based interactive
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based interactive distraction
Study: 33813580
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: 35686900
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% permethrin and oral placebo (Group A)
Study: 35686900
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo cream and oral ivermectin (Group B)
Study: 35686900
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% gamma benzene hexachloride and oral placebo (Group C)
Study: 35686900
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% permethrin and oral ivermectin (Group D)
Study: 32392715
Drug: Intensive Lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Lifestyle Treatment (ILT) - diet plus exercise with monthly visits
Study: 38743692
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated vaccine (TIV)
Study: 35689818
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L polyethylene glycol and ascorbate (PEG/Asc)
Study: 32737604
Drug: Dose-Response Mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-Response Mixed Models for Repeated Measures (DR-MMRM)
Study: 32737604
Drug: Dose-response model
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-response model
Study: 35021015
Drug: Linguistic-phonological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linguistic-phonological intervention to eliminate anterior oral CSCs
Study: 35021015
Drug: Motor-phonetic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor-phonetic intervention to eliminate anterior oral CSCs
Study: 35021015
Drug: Motor-phonetic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor-phonetic intervention to eliminate non-oral CSCs